Alterations of microRNAs and their targets are associated with acquired resistance of MCF‐7 breast cancer cells to cisplatin

Cancer cells that develop resistance to chemotherapeutic agents are a major clinical obstacle in the successful treatment of breast cancer. Acquired cancer chemoresistance is a multifactorial phenomenon, involving various mechanisms and processes. Recent studies suggest that chemoresistance may be linked to drug‐induced dysregulation of microRNA function. Furthermore, mounting evidence indicates the existence of similarities between drug‐resistant and metastatic cancer cells in terms of resistance to apoptosis and enhanced invasiveness. We studied the role of miRNA alterations in the acquisition of cisplatin‐resistant phenotype in MCF‐7 human breast adenocarcinoma cells. We identified a total of 103 miRNAs that were overexpressed or underexpressed (46 upregulated and 57 downregulated) in MCF‐7 cells resistant to cisplatin. These differentially expressed miRNAs are involved in the control of cell signaling, cell survival, DNA methylation and invasiveness. The most significantly dysregulated miRNAs were miR‐146a, miR‐10a, miR‐221/222, miR‐345, miR‐200b and miR‐200c. Furthermore, we demonstrated that miR‐345 and miR‐7 target the human multidrug resistance‐associated protein 1. These results suggest that dysregulated miRNA expression may underlie the abnormal functioning of critical cellular processes associated with the cisplatin‐resistant phenotype.

[1]  William C Reinhold,et al.  MicroRNAs modulate the chemosensitivity of tumor cells , 2008, Molecular Cancer Therapeutics.

[2]  G. Berx,et al.  DeltaEF1 is a transcriptional repressor of E-cadherin and regulates epithelial plasticity in breast cancer cells , 2005, Oncogene.

[3]  G. Goodall,et al.  The microRNA-200 Family Regulates Epithelial to Mesenchymal Transition , 2008, TheScientificWorldJournal.

[4]  K. Uzawa,et al.  Establishment and characterization of a cisplatin-resistant cell line, KB-R, derived from oral carcinoma cell line, KB. , 2007, International journal of oncology.

[5]  S. Raguz,et al.  Resistance to chemotherapy: new treatments and novel insights into an old problem , 2008, British Journal of Cancer.

[6]  A. Scorilas,et al.  Molecular profile of breast versus ovarian cancer cells in response to treatment with the anticancer drugs cisplatin, carboplatin, doxorubicin, etoposide and taxol , 2008, Biological chemistry.

[7]  L. O’Driscoll,et al.  Biomarkers and multiple drug resistance in breast cancer. , 2006, Current cancer drug targets.

[8]  R. J. McDonald,et al.  Role of epigenetic effectors in maintenance of the long-term persistent bystander effect in spleen in vivo. , 2007, Carcinogenesis.

[9]  Z. Siddik,et al.  Cisplatin: mode of cytotoxic action and molecular basis of resistance , 2003, Oncogene.

[10]  R. Foisner,et al.  The transcription factor ZEB1 (deltaEF1) represses Plakophilin 3 during human cancer progression. , 2007, FEBS letters.

[11]  I. Pogribny,et al.  A sensitive new method for rapid detection of abnormal methylation patterns in global DNA and within CpG islands. , 1999, Biochemical and biophysical research communications.

[12]  M. Yamashita,et al.  TRAF6 mediates Smad-independent activation of JNK and p38 by TGF-beta. , 2008, Molecular cell.

[13]  D. Botstein,et al.  Cluster analysis and display of genome-wide expression patterns. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[14]  C. Morrison,et al.  MicroRNA-29 family reverts aberrant methylation in lung cancer by targeting DNA methyltransferases 3A and 3B , 2007, Proceedings of the National Academy of Sciences.

[15]  O. Kovalchuk,et al.  Loss of DNA methylation and histone H4 lysine 20 trimethylation in human breast cancer cells is associated with aberrant expression of DNA methyltransferase 1, Suv4-20h2 histone methyltransferase and methyl-binding proteins , 2006, Cancer biology & therapy.

[16]  A. Scorilas,et al.  Breast Cancer Cells Response to the Antineoplastic Agents Cisplatin, Carboplatin, and Doxorubicin at the mRNA Expression Levels of Distinct Apoptosis‐Related Genes, Including the New Member, BCL2L12 , 2007, Annals of the New York Academy of Sciences.

[17]  G. Hortobagyi,et al.  Overview of resistance to systemic therapy in patients with breast cancer. , 2007, Advances in experimental medicine and biology.

[18]  Olga Kovalchuk,et al.  Involvement of microRNA-451 in resistance of the MCF-7 breast cancer cells to chemotherapeutic drug doxorubicin , 2008, Molecular Cancer Therapeutics.

[19]  Domenico Coppola,et al.  MicroRNA-221/222 Negatively Regulates Estrogen Receptorα and Is Associated with Tamoxifen Resistance in Breast Cancer* , 2008, Journal of Biological Chemistry.

[20]  A. Jemal,et al.  Cancer Statistics, 2008 , 2008, CA: a cancer journal for clinicians.

[21]  H. Coley.  Mechanisms and strategies to overcome chemotherapy resistance in metastatic breast cancer. , 2008, Cancer treatment reviews.

[22]  T. Fojo.  Multiple paths to a drug resistance phenotype: mutations, translocations, deletions and amplification of coding genes or promoter regions, epigenetic changes and microRNAs. , 2007, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

[23]  G. Mariani,et al.  Multidrug resistance in cancer: its mechanism and its modulation. , 2007, Drug news & perspectives.

[24]  Héctor Peinado,et al.  Snail, Zeb and bHLH factors in tumour progression: an alliance against the epithelial phenotype? , 2007, Nature Reviews Cancer.

[25]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.

[26]  R. Weinberg,et al.  Tumour invasion and metastasis initiated by microRNA-10b in breast cancer , 2007, Nature.

[27]  Z. Siddik.  Biochemical and molecular mechanisms of cisplatin resistance. , 2002, Cancer treatment and research.

[28]  L. Kèlland,et al.  The resurgence of platinum-based cancer chemotherapy , 2007, Nature Reviews Cancer.

[29]  Gail Mandel,et al.  Homeostatic regulation of MeCP2 expression by a CREB-induced microRNA , 2007, Nature Neuroscience.

[30]  Terence P. Speed,et al.  A comparison of normalization methods for high density oligonucleotide array data based on variance and bias , 2003, Bioinform..

[31]  D. Medina,et al.  Re-evaluation of mammary stem cell biology based on in vivo transplantation , 2008, Breast Cancer Research.

[32]  Hua Zhao,et al.  A functional polymorphism in the miR-146a gene and age of familial breast/ovarian cancer diagnosis. , 2008, Carcinogenesis.

[33]  P. Johnston,et al.  Molecular mechanisms of drug resistance , 2005, The Journal of pathology.

[34]  O. Kovalchuk,et al.  Epigenetic profiling of multidrug-resistant human MCF-7 breast adenocarcinoma cells reveals novel hyper- and hypomethylated targets , 2007, Molecular Cancer Therapeutics.

[35]  H. Dressman,et al.  Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer. , 2008, JAMA.

[36]  Tyler E. Miller,et al.  MicroRNA-221/222 Confers Tamoxifen Resistance in Breast Cancer by Targeting p27Kip1*♦ , 2008, Journal of Biological Chemistry.

[37]  Massimo Negrini,et al.  Breast cancer metastasis: a microRNA story , 2008, Breast Cancer Research.

[38]  Thomas D. Schmittgen,et al.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. , 2001, Methods.

[39]  D. Baltimore,et al.  NF-κB-dependent induction of microRNA miR-146, an inhibitor targeted to signaling proteins of innate immune responses , 2006, Proceedings of the National Academy of Sciences.

[40]  Stijn van Dongen,et al.  miRBase: tools for microRNA genomics , 2007, Nucleic Acids Res..

[41]  M. Kool,et al.  A family of drug transporters: the multidrug resistance-associated proteins. , 2000, Journal of the National Cancer Institute.

[42]  G. Goodall,et al.  The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1 , 2008, Nature Cell Biology.

[43]  R. Hazan,et al.  Differential Cadherin Expression: Potential Markers for Epithelial to Mesenchymal Transformation During Tumor Progression , 2007, Journal of Mammary Gland Biology and Neoplasia.

[44]  R. Foisner,et al.  The transcription factor ZEB1 (δEF1) promotes tumour cell dedifferentiation by repressing master regulators of epithelial polarity , 2007, Oncogene.

[45]  M. Clynes,et al.  Examining the relationship between cancer invasion/metastasis and drug resistance. , 2002, Current cancer drug targets.

[46]  Molly Megraw,et al.  miRGen: a database for the study of animal microRNA genomic organization and function , 2006, Nucleic Acids Res..